GIP/GLP-1 Dual Agonists: How to Select the Right Agent Within the Class

What Makes GIP/GLP-1 Dual Agonists a Distinct Drug Class

The GIP/GLP-1 dual agonist class is pharmacologically separate from selective GLP-1 receptor agonists such as semaglutide or liraglutide. Every molecule in this class binds two incretin receptors with meaningful potency at each, producing additive or synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and adipose tissue metabolism that a single-receptor agonist cannot fully replicate.

Mechanism at the Receptor Level

Tirzepatide is a 39-amino-acid synthetic peptide engineered with a C18 fatty diacid moiety that extends its half-life to approximately five days, enabling once-weekly subcutaneous dosing. It activates the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously. GIPR activation in adipose tissue reduces lipotoxicity and may improve insulin sensitivity through pathways that are largely GLP-1R-independent. GLP-1R activation drives the well-characterized downstream effects: glucose-dependent insulin release, suppression of postprandial glucagon, slowed gastric emptying, and reduced appetite via central hypothalamic signaling.

The net result is a molecule that addresses both postprandial glucose excursions and fasting hyperglycemia more completely than GLP-1R agonism alone. A 2021 mechanistic study in Cell Metabolism confirmed that GIPR agonism in rodent and human adipocyte models reduces intracellular triglyceride accumulation independently of GLP-1R effects [1].

Why Dual Receptor Engagement Matters Clinically

A question clinicians often raise: if GIP was historically considered "diabetogenic" in the context of obesity (due to blunted response), why add GIP agonism? The answer is that supraphysiologic GIP receptor stimulation overcomes the receptor downregulation seen in insulin-resistant states, restoring the incretin effect in tissue that has become partially resistant to it [2]. This is one reason tirzepatide's weight loss ceiling exceeds what selective GLP-1R agonists produce at maximal approved doses.

Approved Agents in the Class and Their Labeled Indications

Currently, tirzepatide is the only FDA-approved GIP/GLP-1 dual agonist. It is marketed under two brand names that correspond to distinct prescribing pathways and formulations.

Mounjaro (Tirzepatide for Type 2 Diabetes)

The FDA approved Mounjaro in May 2022 for glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise [3]. The SURPASS clinical program (five phase 3 trials) defined its efficacy profile. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.37 percentage points at 40 weeks versus 1.86 percentage points for semaglutide 1 mg (P<0.001) [4]. Weight loss in the same arm reached 12.4 kg versus 6.2 kg for semaglutide.

In SURPASS-4 (N=2,002), patients with high cardiovascular risk achieved HbA1c reductions of 2.58% (15 mg) without an excess of major adverse cardiovascular events versus insulin glargine over 104 weeks [5].

Zepbound (Tirzepatide for Chronic Weight Management)

The FDA approved Zepbound in November 2023 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity [6]. SURMOUNT-1 (N=2,539) remains the key trial: at 72 weeks, the 15 mg arm achieved a mean weight reduction of 22.5% versus 2.4% for placebo (P<0.001), and 36.2% of participants lost 25% or more of body weight [7]. The 10 mg arm still produced 21.4% mean weight reduction, making even submaximal doses clinically meaningful.

SURMOUNT-2 (N=938) enrolled adults with obesity and type 2 diabetes and showed 15.7% mean weight loss at 72 weeks on 15 mg versus 3.3% for placebo [8].

OSA Indication

In June 2024, the FDA approved Zepbound as the first pharmacologic therapy for moderate-to-severe obstructive sleep apnea in adults with obesity. The SURMOUNT-OSA program (two trials, N=469 combined) demonstrated a 25-event-per-hour reduction in the apnea-hypopnea index (AHI) with tirzepatide 10 or 15 mg versus 5 events per hour for placebo at 52 weeks [9]. Roughly half of participants on tirzepatide achieved AHI remission (defined as AHI <5 events per hour or <10 with a 50% or greater reduction).

HFpEF Indication

The FDA approved tirzepatide for heart failure with preserved ejection fraction (HFpEF) plus obesity in 2024, based on the SUMMIT trial (N=731). At 52 weeks, tirzepatide produced a statistically significant improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) and a 38% reduction in the risk of worsening heart failure or cardiovascular death versus placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95, P<0.001) [10].

Dosing Protocol and Titration

Tirzepatide uses a structured escalation schedule designed to minimize gastrointestinal tolerability issues. Starting at 2.5 mg once weekly for four weeks, the dose increases by 2.5 mg every four weeks as tolerated. The maintenance dose range runs from 5 mg to 15 mg once weekly depending on individual response and tolerability.

Titration Decision Points

If a patient cannot tolerate a dose escalation (nausea, vomiting grade 2 or higher, or significant gastroparesis symptoms), extend the current dose for an additional four weeks before attempting the next increment. Dose reductions after a patient has stabilized on a higher dose are acceptable and do not permanently limit the ceiling dose.

For T2D prescribing, no dose adjustment is required for mild-to-moderate renal impairment. Use with caution in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to limited data, though the FDA label does not mandate a specific dose reduction in this population [3].

Administration Technique

Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. The injection site should be rotated weekly. Co-administration at the same site as insulin is acceptable but should use a different injection spot within that region. Refrigeration (36 to 46 degrees Fahrenheit) is required; the pen can be stored at room temperature up to 86 degrees Fahrenheit for up to 21 days.

Comparing Tirzepatide to Selective GLP-1R Agonists: What the Data Show

Head-to-head data comparing tirzepatide to semaglutide in the obesity indication came from SURMOUNT-5 (published 2025, N=751). Participants without diabetes randomized to tirzepatide 10 or 15 mg achieved 20.2% mean weight loss at 72 weeks versus 13.7% for semaglutide 2.4 mg, an absolute difference of 6.5 percentage points (P<0.001) [11]. This is the most direct efficacy comparison available and gives prescribers a clear benchmark.

Glycemic Efficacy Comparison

SURPASS-2 already showed tirzepatide 15 mg outperforming semaglutide 1 mg on HbA1c by 0.51 percentage points. That delta may appear modest in isolation, but for patients near their HbA1c target, 0.5 points can represent the difference between meeting a glycemic goal and adding a second agent [4].

Gastrointestinal Tolerability

GI side effect profiles are qualitatively similar between tirzepatide and semaglutide. In SURMOUNT-1, nausea occurred in 31% of participants on tirzepatide 15 mg versus 10% for placebo, and vomiting in 13% versus 3% [7]. Rates are generally comparable to those reported in the STEP-1 trial for semaglutide 2.4 mg (nausea 44%, vomiting 24%), though cross-trial comparisons require caution given different patient populations and study designs [12].

Hypoglycemia Risk

Like all incretin-based therapies, tirzepatide carries a low intrinsic hypoglycemia risk as monotherapy because insulin secretion is glucose-dependent. When combined with a sulfonylurea or insulin, the risk increases substantially. In SURPASS-2, symptomatic hypoglycemia occurred in 7.8% of the tirzepatide 15 mg arm, driven largely by patients on background sulfonylureas [4]. Proactive dose reduction of the sulfonylurea or basal insulin when initiating tirzepatide is appropriate clinical practice.

Selecting Tirzepatide: Indication-Specific Decision Framework

The four FDA-approved indications map to distinct clinical scenarios. The following framework reflects how a prescriber should think through indication alignment before initiating therapy.

Scenario 1: Obesity Without T2D

Use Zepbound (tirzepatide) when the patient has a BMI of 30 or above, or a BMI of 27 or above with a weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. SURMOUNT-1 and SURMOUNT-5 data make it the most effective pharmacologic weight-loss agent with an approved label. Semaglutide 2.4 mg (Wegovy) is a reasonable alternative if tirzepatide is unavailable or cost-prohibitive, but the weight loss ceiling is lower.

Scenario 2: Type 2 Diabetes With Obesity

Mounjaro (tirzepatide) addresses both targets simultaneously. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists or dual GIP/GLP-1 agonists as preferred add-on therapy after metformin in patients who need weight management or cardiovascular risk reduction, provided cost and access allow [13]. Tirzepatide's superior HbA1c and weight reduction data relative to semaglutide 1 mg make it the preferred choice when both targets are meaningful. If the patient also has established ASCVD or high cardiovascular risk, tirzepatide is still appropriate; cardiovascular outcomes data from SURPASS-CVOT are expected in 2025 to 2026.

Scenario 3: OSA Plus Obesity

Tirzepatide (Zepbound) is the only pharmacologic option with an FDA label for this combination. The prescriber should coordinate with the patient's sleep medicine team. Patients using CPAP should continue it during therapy; SURMOUNT-OSA showed AHI improvements both in CPAP users and non-users, and some participants were able to discontinue CPAP after achieving AHI remission on tirzepatide [9].

Scenario 4: HFpEF Plus Obesity

The SUMMIT trial enrolled patients with HFpEF (EF 45% or above) and a BMI of 30 or above. The 38% relative risk reduction in worsening HF events is clinically meaningful in a population with very few effective pharmacologic options [10]. Prescribers should work within a heart failure care team. The combination of tirzepatide with SGLT2 inhibitors (which have their own HFpEF outcomes data) is common in practice but has not been studied in a dedicated RCT; expect guidance from upcoming real-world data.

Contraindications, Precautions, and Drug Interactions

Absolute Contraindications

The FDA label for tirzepatide carries a black-box warning for thyroid C-cell tumors based on rodent carcinogenicity data. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). The relevance of the rodent data to humans remains under investigation, but the contraindication stands until human long-term thyroid cancer data are available [3].

Pancreatitis is a labeled precaution, not an absolute contraindication, though tirzepatide should not be restarted after confirmed acute pancreatitis. Patients with a history of pancreatitis require individual risk-benefit discussion.

Drug Interactions

Tirzepatide slows gastric emptying, which can reduce peak plasma concentrations of oral medications that depend on rapid absorption. Oral contraceptives are a clinically relevant example. Patients should be counseled to use a non-oral or barrier contraceptive method during the first month of each dose escalation, consistent with advice in the prescribing label [3]. Warfarin INR should be monitored more frequently during initiation and titration because gastric emptying changes can affect absorption kinetics.

Pipeline Agents in the GIP/GLP-1 and Related Classes

Tirzepatide will not be the only option in this space for long.

Retatrutide (GIP/GLP-1/Glucagon Triple Agonist)

Retatrutide (LY3437943, Eli Lilly) activates the GIP receptor, GLP-1 receptor, and glucagon receptor simultaneously. Phase 2 data (N=338) published in the New England Journal of Medicine in 2023 showed mean weight loss of 24.2% at 48 weeks on the 12 mg dose, with some participants exceeding 30% weight reduction [14]. Phase 3 trials are enrolling. Adding glucagon receptor agonism theoretically increases energy expenditure, which may explain the higher weight loss ceiling compared with tirzepatide.

Maritide and Other Pipeline Molecules

Maritide (AMG 133, Amgen) is a GLP-1R agonist / GIPR antagonist. It takes the opposite approach to GIPR: rather than activating the receptor, it blocks it while agonizing GLP-1R. Phase 2 data suggest durable weight loss of approximately 20% at 52 weeks with monthly dosing. Whether GIPR antagonism produces equivalent or superior outcomes to GIPR agonism remains an active research question that Phase 3 data will need to answer.

Practical Prescribing Checklist

Before writing the first prescription, confirm the following:

• Indication alignment: BMI criteria met, or T2D diagnosis confirmed, or OSA/HFpEF documented.
• Contraindication screen: No personal or family history of MTC or MEN2. No active or recent pancreatitis. No severe gastroparesis.
• Baseline labs: HbA1c (all patients), fasting glucose, comprehensive metabolic panel, lipids, and thyroid function if clinically indicated.
• Concomitant medications: Insulin or sulfonylurea dose reduction plan in place before initiating. Oral contraceptive counseling documented. Warfarin monitoring plan if applicable.
• Patient counseling: Weekly injection technique, refrigeration requirements, expected timeline (weight loss trajectory typically shows meaningful response by week 12 to 16 at doses of 5 mg or higher), and the importance of continued lifestyle modification.
• Prior authorization: Both Mounjaro and Zepbound require PA from most payers. Initiate PA before the first prescription to avoid gaps.

The American Association of Clinical Endocrinology's 2023 obesity guidelines state: "GIP/GLP-1 receptor agonists represent the most effective pharmacologic obesity therapy currently available and should be considered first-line injectable therapy in appropriate candidates." [15]

Monitoring and Long-Term Management

After starting tirzepatide, schedule a follow-up visit at four weeks to assess tolerability and confirm the dose escalation. For T2D patients, check HbA1c at 12 weeks. For weight management, assess body weight percentage change at 12 and 24 weeks; patients who have not lost at least 5% of body weight by week 16 at an adequate dose may warrant reassessment of adherence, dose timing, and caloric intake before considering a switch.

Thyroid ultrasound is not routinely indicated in the absence of a palpable nodule or elevated calcitonin. Monitor for signs of pancreatitis (severe abdominal pain radiating to the back) and counsel patients to seek emergency care if this occurs.

Treat tirzepatide as chronic therapy. SURMOUNT-4 (N=783) demonstrated that patients who lost weight on tirzepatide and then switched to placebo regained two-thirds of their lost weight within 52 weeks [16]. Discontinuation should be a shared decision with an explicit re-engagement plan in place.

In SURMOUNT-1, 63% of participants on tirzepatide 15 mg achieved a weight loss of 20% or more at 72 weeks [7]. That number gives patients a realistic expectation to work toward.